Is DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE the same as IYUZEH?

No. DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE (DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE) and IYUZEH (LATANOPROST OPHTHALMIC SOLUTION 0.005%) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE or LATANOPROST OPHTHALMIC SOLUTION 0.005%?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE to LATANOPROST OPHTHALMIC SOLUTION 0.005%?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE vs LATANOPROST OPHTHALMIC SOLUTION 0.005%

Compare DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE (DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE) and LATANOPROST OPHTHALMIC SOLUTION 0.005% (IYUZEH) — clinical data, side effects, and patient experiences.

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE · Glaucoma Agent

How it works

12.1 Mechanism of Action Dorzolamide hydrochloride and timolol maleate ophthalmic solution is comprised of two components: Dorzolamide hydrochloride and timolol maleate. Each of th...

Approved for

a carbonic anhydrase inhibitor

and timolol maleate

a beta-adrenergic receptor blocking agent

and 2% dorzolamide three times daily. ( 1 )

OphthalmicTablet

LATANOPROST OPHTHALMIC SOLUTION 0.005%

IYUZEH · Glaucoma Agent

How it works

12.1 Mechanism of Action Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man sugg...

Approved for

See full prescribing information

OphthalmicTablet

Quick Comparison

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATELATANOPROST OPHTHALMIC SOLUTION 0.005%

Drug Class

Glaucoma Agent

Route

Ophthalmic

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE

Drug Not Working

>10%

Fatigue

1-10%

Headache

0.1-1%

Blurred Vision

0.1-1%

Shortness of Breath

0.1-1%

LATANOPROST OPHTHALMIC SOLUTION 0.005%

Drug Not Working

>10%

Fatigue

1-10%

Headache

1-10%

Shortness of Breath

1-10%

Blurred Vision

1-10%

Dizziness

1-10%

Diarrhea

0.1-1%

Nausea

0.1-1%

FDA Warnings

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE

5 WARNINGS AND PRECAUTIONS Potentiation of Respiratory Reactions Including Asthma ( 5
For example, severe respiratory reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate [see Contraindications ( 4
Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias
If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation [see Contraindications ( 4

LATANOPROST OPHTHALMIC SOLUTION 0.005%

5 WARNINGS AND PRECAUTIONS Pigmentation : Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur
IYUZEH should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema

Clinical Trial Data

No head-to-head clinical studies found for DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE vs LATANOPROST OPHTHALMIC SOLUTION 0.005%.

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE vs LATANOPROST OPHTHALMIC SOLUTION 0.005%: What You Should Know

Key Differences

Both DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE and LATANOPROST OPHTHALMIC SOLUTION 0.005% belong to the Glaucoma Agent class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE carries 4 FDA warnings. LATANOPROST OPHTHALMIC SOLUTION 0.005% carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE vs TRAVOPROST OPHTHALMIC SOLUTION→DORZOLAMIDE HYDROCHLORIDE vs DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE→DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION vs DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE→DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE vs LATANOPROST OPHTHALMIC SOLUTION→DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE vs TRAVOPROST→BRIMONIDINE TARTRATE vs DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov
LATANOPROST OPHTHALMIC SOLUTION 0.005%: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE vs LATANOPROST OPHTHALMIC SOLUTION 0.005%

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE · Glaucoma Agent

How it works

12.1 Mechanism of Action Dorzolamide hydrochloride and timolol maleate ophthalmic solution is comprised of two components: Dorzolamide hydrochloride and timolol maleate. Each of th...

Approved for

a carbonic anhydrase inhibitor

and timolol maleate

a beta-adrenergic receptor blocking agent

and 2% dorzolamide three times daily. ( 1 )

OphthalmicTablet

LATANOPROST OPHTHALMIC SOLUTION 0.005%

IYUZEH · Glaucoma Agent

How it works

12.1 Mechanism of Action Latanoprost is a prostaglandin F 2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man sugg...

Approved for

See full prescribing information

OphthalmicTablet

Quick Comparison

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATELATANOPROST OPHTHALMIC SOLUTION 0.005%

Drug Class

Glaucoma Agent

Route

Ophthalmic

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE

Drug Not Working

>10%

Fatigue

1-10%

Headache

0.1-1%

Blurred Vision

0.1-1%

Shortness of Breath

0.1-1%

LATANOPROST OPHTHALMIC SOLUTION 0.005%

Drug Not Working

>10%

Fatigue

1-10%

Headache

1-10%

Shortness of Breath

1-10%

Blurred Vision

1-10%

Dizziness

1-10%

Diarrhea

0.1-1%

Nausea

0.1-1%

FDA Warnings

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE

5 WARNINGS AND PRECAUTIONS Potentiation of Respiratory Reactions Including Asthma ( 5
For example, severe respiratory reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate [see Contraindications ( 4
Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias
If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation [see Contraindications ( 4

LATANOPROST OPHTHALMIC SOLUTION 0.005%

5 WARNINGS AND PRECAUTIONS Pigmentation : Pigmentation of the iris, periorbital tissue (eyelid) and eyelashes can occur
IYUZEH should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema

Clinical Trial Data

No head-to-head clinical studies found for DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE vs LATANOPROST OPHTHALMIC SOLUTION 0.005%.

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE vs LATANOPROST OPHTHALMIC SOLUTION 0.005%: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALEATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov
LATANOPROST OPHTHALMIC SOLUTION 0.005%: DailyMed label · FAERS adverse events · ClinicalTrials.gov